Vaccine Code Set Update Publication Date: December 21, 2022
The individual filenames included in this distribution contain the publication date (20221221)
Release Notes: This release includes updates for all vaccine codes and maps.
Release notes are designed as a guide to highlight changes that have been made to the vaccine codes since the last publication. They should not be used as the primary source of code information. The vaccine code files themselves should be utilized.
General Note Regarding This Release: Codes with "Last Update" dates from 12/9/2022 to 12/19/2022, reflect the changes and additions in this release. This release includes the following code set updates:
Vaccine Code Set Update Summary
- COVID-19 Related Code Updates
- Non-US Vaccines. Two CVX code short names updated; one note field updated.
- Vaccine Code Set Updates Not Related to COVID-19
CVX Code Updates:
- Influenza CVX codes. Three CVX codes have been inactivated: All three represent CVX codes where there are no active NDCs and the last active NDC was retired prior to 12/21/2019. In addition to the CVX status change, the following updates relating to the CVX inactivation were made:
- All product/Tradename records associated to each CVX code were set to "retired".
- Retired CVX codes removed from current influenza VIS CVX to VIS map.
- Ebola CVX code. CVX code 204 note field updated to reflect that the Ervebo product has been FBA approved, but NDCs are not yet listed in the FDA files.
NDC Code Updates:
- NDCs Added – Menveo new single vial presentation
- New Unit of Sale and Unit of Use NDCs added and associated to CVX code 136.
- Existing NDCs for Menveo Kit presentations updated – NDC description updated to add word "kit".
- NDCs retired – INFANRIX vial presentation
- Unit of Sale and Unit of Use NDC end dates set to 12/14/2022.
Vaccine Code Set Update Details
The core CDC IIS vaccine data code sets have been updated to reflect the changes in this release. These can be found at IIS Data Code Sets | CDC
The COVID-19 Related Codes Table for non-US Vaccines has been updated to reflect the changes in this release. These can be found at IIS COVID-19 Vaccine Related Code | CDC
- COVID-19 Related Code Updates
- Non-US Vaccine CVX Codes Updated:
- CVX Code 506 Short Name has been changed to "COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology".
- CVX Code 506 Short Name has been changed to "COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech". In addition, Note field has been updated to add WHO authorization date.
- Vaccine Code Updates Not Related to COVID-19
- CVX Code Updates: Influenza CVX Codes
- Influenza CVX codes 140, 144, and 166 have had their status set to "inactive". All three represent CVX codes where there are no active NDCs and the last active NDC was retired prior to 12/21/2019.
- CVX code mappings from these CVX to VIS Document ID 253088698300010311210806, "Influenza (Flu) Vaccine (Inactivated or Recombinant) VIS" with Edition Date 08/06/2021 have been removed.
The table below identifies all the product/tradenames associated to each CVX. The Product records' status have been set to "retired" along with the CVX codes:
CVX Code | CVX Description | CVX Status | CVX Retired Effective Date | Product Tradename | Manufacturer Labeler | Product Tradename Last NDC Retired Date |
|---|
140 | Influenza, seasonal, injectable, preservative free | Inactive | 12/20/2019 | Afluria, preservative free | Seqirus | 12/20/2019 |
|---|
Flulaval, preservative free | ID Biomedical | 10/31/2015 |
|---|
Fluvirin preservative free | Seqirus | 6/30/2018 |
|---|
FLUARIX | GlaxoSmithKline | 6/30/2015 |
|---|
FLUVIRIN-PRESERVATIVE FREE | Novartis Pharmaceutical Corporation | 6/30/2016 |
|---|
FLUZONE-PRESERVATIVE FREE | Sanofi Pasteur | 6/30/2015 |
|---|
Afluria, preservative free | bioCSL | 6/30/2016 |
|---|
144 | seasonal influenza, intradermal, preservative free | Inactive | 6/30/2015 | Fluzone, intradermal | Sanofi Pasteur | 6/30/2015 |
|---|
166 | influenza, intradermal, quadrivalent, preservative free, injectable | Inactive | 6/30/2018 | Fluzone Quad Intradermal | Sanofi Pasteur | 6/30/2018 |
|---|
- CVX Code Updates: Ebola CVX Code 204
- The Note field has been updated to "FDA Approved ERVEBO Vaccine. NDCs and SPL not yet listed".
- At this time, the manufacturer NDC listings on the FDA File and in DailyMed are not yet available in final form.
- New NDCs for Menveo
- The following new NDC pair for Menveo has been added. This represents a new single vial presentation that is premixed and includes both components that are separately provided in the other kit presentations of Menveo. A new CVX code has not been added. The NDCs are mapped to existing CVX code 136 and MVX code SKB as applied to other Menveo Kit presentation NDCs.
New NDCs for Menveo added and mapped to existing CVX and MVX codes
Sale Proprietary Name | Sale Labeler | Unit of Sale NDC11 | Unit of Use NDC11 | CVX Code | CVX Description | MVX Code |
|---|
Menveo | GlaxoSmithKline Biologicals SA | 58160-0827-30 | 58160-0827-03 | 136 | meningococcal oligosaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4O) | SKB |
|---|
- Retired NDCs for INFANRIX
- The following NDC codes for a vial presentation have been retired in this code set release. At this time, NDC codes for a syringe presentation remail active.
Sale Proprietary Name | Sale Labeler | Unit of Sale NDC11 | Unit of Use NDC11 |
|---|
INFANRIX | GlaxoSmithKline Biologicals SA | 58160-0810-01 | 58160-0810-11 |
|---|
- Final Note
- In addition to the NDC updates listed above, FDA files received and processed by the CDC included minor changes to a number of NDCs. These changes did not impact CDC codes or information published in the CDC files. However, the updates did change the date of last update on the affected records.
